Saving on Medicines: Germany Risks Disconnecting from Medical Progress

Berlin – Germany's pharmaceutical industry is voicing deep concern over the country's drug pricing policies, which experts warn could lead to its disconnection from medical progress. Analysts at the IGES Institute have examined the implications of the United States' "Most Favored Nation" (MFN) drug pricing initiative for Germany.

The MFN principle aims to ensure the U.S. does not pay more for new medications than other developed nations. This stems from the U.S. administration's view that other countries, including Germany, benefit from U.S. investment in research and development by paying lower prices. The IGES Institute highlights that the U.S. market, representing 67% of the global market for innovative drugs, is significantly more expensive than Europe's (20%) and Germany's (4%).

An analysis by IGES indicates that U.S. list prices for innovative drugs were, on average, 3.2 times higher than in Germany and other comparison countries between 2018 and 2023. By 2023, this disparity had widened, with U.S. prices reaching 4.7 times those in Germany. While the MFN policy aims to lower U.S. prices, its implementation and consequences for access to medicines in Germany remain uncertain.

Industry representatives express apprehension, stating a desire to make their products available but acknowledging that continued austerity measures and a weakened competitive position in Germany could make this increasingly difficult. This situation raises questions about Germany's ability to keep pace with medical advancements and ensure future access to innovative treatments.